Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trialcancerlungtreatmentDual inhibition of vascular endothelial growth factor and epidermal growth factor receptor ...
Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer Cell Oncol, 36 (2013), pp. 277-288 CrossrefView in ScopusGoogle Scholar 28 M.J. Jameson, L.E. Taniguchi, K.K. VanKoevering, M.M. St...
[7] Zhang L, et al. Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): A randomized, double-blind, multi-center, phase 3 ...
EGFR是一种跨膜蛋白,通过配体结合激活,然后与家族其他成员(ERBB2、ERBB3和ERBB4)然后进行同源和/或异源二聚体化和受体的磷酸化,激活下游多种信号通路。 ATP竞争性EGFR酪氨酸激酶抑制剂的成功开发(Tyrosine kinase inhibitors, TKIs),对治疗EGFR突变的NSCLC产生...
Gefitinib(吉非替尼)基础信息 中文名：易瑞沙;吉非替尼;EGFR酪氨酸激酶抑制剂 英文名：Gefitinib, EGFR tyrosine kinase inhibitor;ZD1839;CAS号：184475-35-2 结构式：COc1cc2c(cc1OCCCN3CCOCC3)c(ncn2)Nc4ccc(c(c4)Cl)F 分子式：C22H24ClFN4O3 分子量：446.9 闪点 ：308.7±30.1 °C 沸点：1727°...
5c). The GREM1-induced phosphorylation of ERK and Akt as well as that of EGFR was attenuated by treatment with erlotinib, an EGFR tyrosine kinase inhibitor (Fig. 5d). Fig. 5: GREM1 stimulates EGFR signalling. a–c Effect of GREM1 on EGFR signalling. a SKBR3 cells were starved over...
英文名:Gefitinib, EGFR tyrosine kinase inhibitor;ZD1839; CAS号:184475-35-2 结构式:COc1cc2c(cc1OCCCN3CCOCC3)c(ncn2)Nc4ccc(c(c4)Cl)F 分子式:C22H24ClFN4O3 分子量:446.9 闪点:308.7±30.1 °C 沸点:1727°C 极化度:47.1±0.5 10-24cm3 密度:3.9200 溶解度:溶于DMSO(25°C时89毫克/毫升)、...
10.Lecia V Sequist ,et al.Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.Lancet Oncol.2020 Mar;21(3):373-386...
EGFR, epidermal growth factor receptor; EMT, epithelial-to-mesenchymal transition; mRNA, messenger RNA; PD-1, programmed death receptor-1; PD-L1, programmed death ligand-1; TKI, tyrosine kinase inhibitor. Table 2. Clinical definition27 and subtyping28 of acquired resistance to EGFR-TKIs in lung...
[7] Zhang L, et al. Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): A randomized, double-blind, multi-center, phase 3 trial. 2024 ASCO 8508. ...